Interview: Gary Hendler – Chairman & CEO, Eisai EMEA

Confirming Eisai’s commitment to keeping its EMEA headquarters in the UK, Gary Hendler, chairman and CEO EMEA, and Nick Burgin, COO and president of global value and access stress how the company is looking at Brexit as a glass half full. Eisai views Brexit as an opportunity to bring with it change that will positively impact processes in the UK and push forward a discussion on collaboration between public bodies and industry. Gary, what a major change since we last spoke in 2011: Brexit has been voted for. How do you see Brexit impacting Eisai and how are you preparing your organization for the possible scenarios?
"[Brexit] presents an opportunity for the UK to improve its environment for life sciences"
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In

Related Interviews

Latest Report